Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Insights from 2023 ASCO® Annual Meeting

S. O'Brien, C. Coombs

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Cleveland Clinic Taussig Cancer Institute

A. Winter

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Fixed-Duration Treatment in CLL: Current Considerations

UCI Health

E. Brem

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…

Indy Hematology Review

J. Woyach

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

State-of-the-Art in CLL Treatment

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Cuneo

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…

Insights from 2023 ASH Annual Meeting

M. Shadman

Impact of Ibrutinib Dose Modifications in CLL

Ruemu Birhiray

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain